Evidence map›Paper›PMID 41971416›Full record

ArticleFrontiers in oncology2026

Plasma cfDNA and peripheral blood gDNA provide complementary information for molecular monitoring in myeloproliferative neoplasms.

Xiaotong Ma, Can Yang, Yusi Duan, Huixuan Zhang, Xuemei Tang, Qingyun Zhang, Wenjiao Qin, Wenhao Zhang, Gusheng Tang, Ming Guan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiaotong Ma *Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Can Yang *Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Yusi DuanDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Huixuan ZhangDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Xuemei TangCentral Laboratory, Huashan Hospital, Fudan University, Shanghai, China.
Qingyun ZhangCentral Laboratory, Huashan Hospital, Fudan University, Shanghai, China.
Wenjiao QinDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Wenhao ZhangDepartment of Hematology, the First Affiliated Hospital of Naval Medical University, Shanghai, China.
Gusheng TangDepartment of Hematology, the First Affiliated Hospital of Naval Medical University, Shanghai, China.
Ming GuanDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Zhiyuan WuDepartment of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Molecular monitoring of Philadelphia-negative myeloproliferative neoplasms (MPN) relies on genomic DNA (gDNA) from peripheral blood (PB). As variant allele frequency (VAF) reduction correlates with clinical outcomes, optimizing monitoring strategies has become important. However, whether gDNA accurately reflects bone marrow (BM) clonal dynamics and whether cell-free DNA (cfDNA) provides complementary information remains undefined. Methods: We compared cfDNA and PB gDNA using methylation-based deconvolution, a cell line-derived xenograft (CDX) model, and paired clinical samples from two independent MPN cohorts (technical, n=7 with matched BM; validation, n=40 with longitudinal monitoring). Results: Methylation deconvolution showed an enrichment of BM-derived DNA in cfDNA (47.4% vs 18.9%, Conclusions: While constrained by sample size and specific treatment contexts, our observations suggest that cfDNA and gDNA provide complementary value for MPN monitoring. Supported by preclinical models and technical analysis, cfDNA more effectively reflects BM clonal burden, while longitudinal observations suggest its capacity to track treatment-related clonal dynamics. In contrast, gDNA is more informative in confirming treatment response. The lymphocyte percentage predicts cfDNA utility, enabling rational test selection and a practical framework for optimizing MPN management.

Indexed as

bone marrowcell-free DNAliquid biopsylymphocyte percentagemolecular monitoringmyeloproliferative neoplasmstreatment response

Identifiers

PMID41971416
PMCPMC13065645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.